WINTON GROUP Ltd Takes $570,000 Position in Penumbra, Inc. (NYSE:PEN)

WINTON GROUP Ltd acquired a new stake in shares of Penumbra, Inc. (NYSE:PEN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,400 shares of the company’s stock, valued at approximately $570,000.

Other large investors have also recently modified their holdings of the company. Advisors Asset Management Inc. lifted its stake in shares of Penumbra by 11.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 416 shares of the company’s stock valued at $81,000 after acquiring an additional 43 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Penumbra by 1.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 267,767 shares of the company’s stock valued at $52,030,000 after purchasing an additional 4,848 shares during the last quarter. Cerity Partners LLC boosted its stake in shares of Penumbra by 19.2% during the third quarter. Cerity Partners LLC now owns 3,612 shares of the company’s stock valued at $702,000 after purchasing an additional 583 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Penumbra by 15.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,225 shares of the company’s stock valued at $1,404,000 after purchasing an additional 953 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Penumbra by 1.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 97,571 shares of the company’s stock worth $18,959,000 after purchasing an additional 995 shares during the last quarter. Institutional investors own 88.88% of the company’s stock.

Penumbra Price Performance

Shares of NYSE PEN opened at $267.16 on Friday. The company has a 50 day simple moving average of $274.55 and a two-hundred day simple moving average of $242.90. Penumbra, Inc. has a fifty-two week low of $148.00 and a fifty-two week high of $310.00. The company has a market capitalization of $10.29 billion, a price-to-earnings ratio of 785.75, a P/E/G ratio of 2.83 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01.

Penumbra (NYSE:PEN) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The company had revenue of $315.52 million during the quarter, compared to analyst estimates of $311.63 million. Analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Arani Bose sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $283.77, for a total value of $3,405,240.00. Following the transaction, the director now directly owns 314,819 shares of the company’s stock, valued at approximately $89,336,187.63. This represents a 3.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Harpreet Grewal sold 167 shares of Penumbra stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $241.28, for a total value of $40,293.76. Following the completion of the sale, the director now directly owns 8,530 shares of the company’s stock, valued at approximately $2,058,118.40. The trade was a 1.92 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 93,518 shares of company stock worth $26,400,219 in the last quarter. Corporate insiders own 5.00% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on PEN shares. Bank of America began coverage on shares of Penumbra in a research report on Friday, March 14th. They set a “buy” rating and a $320.00 price target for the company. Royal Bank of Canada increased their target price on shares of Penumbra from $285.00 to $313.00 and gave the stock an “outperform” rating in a report on Wednesday, February 19th. Morgan Stanley boosted their price target on Penumbra from $240.00 to $260.00 and gave the company an “equal weight” rating in a report on Wednesday, February 19th. Wells Fargo & Company increased their price objective on Penumbra from $275.00 to $305.00 and gave the stock an “overweight” rating in a report on Wednesday, February 19th. Finally, Truist Financial boosted their target price on Penumbra from $285.00 to $325.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Penumbra has an average rating of “Moderate Buy” and a consensus target price of $294.47.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.